Study of the efficacy and safety of inhaled Treprostinil in patients with Idiopathic
The purpose of this study is to evaluate the safety and efficacy of inhaled Treprostinil
in subjects with IPF.
Basic Study Information
Purpose:Study Web URL: https://pipeline.unither.com/product/teton-inhaled-treprostinil/description/
You are being asked to be in this research study because you have idiopathic pulmonary
fibrosis (IPF). This means that you have scarring of the lungs from an unknown cause.
The scarring makes it hard for the lungs to get oxygen into the blood, which causes
shortness of breath and coughing.
This research study is being conducted under the direction of R. Matthew Kottmann,
MD, MS-CTR who is the “principal investigator,” also known as the “study doctor.”
As the study doctor, Dr. Kottmann is solely responsible for making sure that this
study is done properly and that your rights and safety, as a participant in this study
are protected. Dr. Kottmann will carry out the day-to-day activities of the research
study in accordance with his independent medical judgment.
United Therapeutics Corp., a drug company, is the “sponsor” of this research study
and is responsible for the development and broad oversight of the study.
Study Reference #: STUDY00006294
Lead Researcher (Principal Investigator)
Study Contact Information
Additional Study Details
Number of Visits:
6 to 10
Learn More About These Conditions
More information about Idiopathic Pulmonary Fibrosis
Trial Not Found
The study you are looking for is not active at this time.
Return to Search